ADAP.Y Share Price Performance
US$0.012
0.01 (0.00%)
99.2% undervalued intrinsic discount
US$1.50
Fair Value
Price US$0.012
AnalystConsensusTarget US$1.50
Fair ValueUS$1.50
Share Pricen/a
Narrative Update • Feb 11
Adaptimmune Therapeutics plc Stock Price
- 1 Narratives written by author
- 0 Comments on narratives written by author
- 29 Fair Values set on narratives written by author
ADAP.Y Community Narratives
AN
Fair Value
·Fair Value US$1.5 99.2% undervalued intrinsic discount
ADAP.Y: Compliance Efforts Will Overcome Index Removal To Drive Recovery
1users have liked this narrative
0users have commented on this narrative
18users have followed this narrative
ADAP.Y: Compliance Efforts Will Overcome Index Removal To Drive Recovery
Key Takeaways Rapid treatment network expansion and successful TECELRA launch are driving significant future revenue growth and patient access. Strategic cost reductions and successful manufacturing are enhancing net margins and paving the way towards long-term profitability.Read more
AN
US$1.5
99.2% undervalued intrinsic discount
Fair Value
Profit Margin
16.05%
Future PE
19.36x
Price in 2029
US$2.18
Trending Discussion
Recently Updated Narratives
AN
ADAP.Y: Executive Transition And Deregistration Will Support Future Upside Potential
Fair Value: US$1.5 99.2% undervalued intrinsic discount
18 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
Adaptimmune Therapeutics plc Key Details
Last Reported Earnings
Jun 30, 2025
Next Reporting Earnings
n/a
- -0.64
- -97.73%
- -260.82%
- -36.2%
About ADAP.Y
- Founded
- 2008
- Employees
- 506
- CEO
- WebsiteView website
Adaptimmune Therapeutics plc, a commercial-stage biopharmaceutical company, provides novel cell therapies primarily to cancer patients in the United States and the United Kingdom. It develops TECELRA (famitresgene autoleucel or afami-cel), a genetically modified autologous T-cell immunotherapy for the treatment of adults with unresectable or metastatic synovial sarcoma; Lete-cel for the treatment of synovial sarcoma and myxoid liposarcoma; and ADP-5701, which is in Phase 1 clinical trial for the treatment of head and neck cancer. The company also focuses on the development of T-cell therapies directed to PRAME (ADP-600) and CD70 (ADP-520). It has a strategic collaboration with Galápagos for a clinical proof-of-concept trial to evaluate the safety and efficacy of uza-cel produced on Galápagos’ decentralized manufacturing platform (ADP-5701) in patients with head and neck cancer; a collaboration and license agreement with Noile-Immune Biotech, Inc. and strategic alliance agreement with the MD Anderson Cancer Center. Adaptimmune Therapeutics plc was founded in 2008 and is headquartered in Abingdon, the United Kingdom.
Recent ADAP.Y News & Updates
Narrative Update • Jan 26
ADAP.Y: Leadership Restructuring And Deregistration Will Set Up Future Upside Potential
Analysts have trimmed their price target on Adaptimmune Therapeutics to US$1.50 from US$1.50, reflecting updated assumptions around profit margin and future P/E, while keeping their fair value view unchanged. What's in the News Adaptimmune Therapeutics plans leadership changes effective November 14, 2025, with Christopher Hill moving from Chief Financial Officer to Chief Executive Officer and joining the Board, following the departure of former CEO Adrian Rawcliffe in connection with a company restructuring (Key Developments).Narrative Update • Jan 12
